SCHEMBL26178951

SCHEMBL26178951

Fc1ccc(-c2cnc3ccc(Br)cn23)cn1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 4/20 0.56
MTOR P42345 4/20 0.56
MAP3K14 Q99558 1/20 0.49
FLT3 P36888 6/20 0.42
DYRK1A Q13627 2/20 0.39
JAK2 O60674 1/20 0.39
RET P07949 1/20 0.39
KDR P35968 1/20 0.39
GSK3A P49840 1/20 0.39
RPS6KA3 P51812 1/20 0.39
LIMK1 P53667 1/20 0.39
MAP2K1 Q02750 1/20 0.39
MAPK14 Q16539 1/20 0.39
CLK4 Q9HAZ1 1/20 0.39
ALK Q9UM73 1/20 0.39
DYRK1B Q9Y463 1/20 0.39
PRMT5 O14744 1/20 0.38
WDR77 Q9BQA1 1/20 0.38
AHR P35869 2/20 0.37
CLK1 P49759 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15756786 0.84 FLT3 (0.59) PIK3CAMTORMAP3K14FLT3DYRK1A
SCHEMBL15288131 0.78 FYN (0.55) PIK3CAMTORMAP3K14FLT3PRMT5
SCHEMBL26178953 0.78 KDR (0.53) PIK3CAMTORMAP3K14FLT3KDR
SCHEMBL15757685 0.77 DYRK1A (0.52) PIK3CAMTORMAP3K14FLT3DYRK1A
SCHEMBL15756965 0.77 MAP3K14 (0.54) PIK3CAMTORMAP3K14FLT3DYRK1A
SCHEMBL22851709 0.76 FLT3 (0.71) PIK3CAMTORFLT3DYRK1AKDR
SCHEMBL4254179 0.76 MAP3K14 (0.56) PIK3CAMTORMAP3K14FLT3KDR
SCHEMBL15756997 0.75 PIK3CA (0.55) PIK3CAMTORMAP3K14FLT3MAPK14
SCHEMBL18041661 0.74 PIK3CA (0.47) PIK3CAMTORMAP3K14FLT3AHR
SCHEMBL19586821 0.74 PIK3CA (0.65) PIK3CAMTORMAP3K14FLT3DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230190717-A1 P38 GAMMA INHIBITORS AND METHOD OF USE THEREOF CITY OF HOPE 2023-06-22 US disclosed
US-20230190717-A1 P38 GAMMA INHIBITORS AND METHOD OF USE THEREOF CITY OF HOPE 2023-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230190717-A1 P38 GAMMA INHIBITORS AND METHOD OF USE THEREOF CDC42BPG, MAPK1, MAPK7 PIK3CA 261/4885MTOR 752/4885MAP3K14 34/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.